Albion Financial Group UT Sells 130 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Albion Financial Group UT lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% during the first quarter, HoldingsChannel reports. The firm owned 26,177 shares of the medical research company’s stock after selling 130 shares during the quarter. Thermo Fisher Scientific makes up 1.2% of Albion Financial Group UT’s investment portfolio, making the stock its 24th largest position. Albion Financial Group UT’s holdings in Thermo Fisher Scientific were worth $15,214,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Northwest Financial Advisors bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $29,000. True Wealth Design LLC grew its holdings in Thermo Fisher Scientific by 1,275.0% in the 4th quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after buying an additional 51 shares in the last quarter. Pineridge Advisors LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $39,000. Cape Investment Advisory Inc. grew its holdings in Thermo Fisher Scientific by 52.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company’s stock valued at $40,000 after buying an additional 26 shares in the last quarter. Finally, Raleigh Capital Management Inc. grew its holdings in Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after buying an additional 27 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on TMO shares. JPMorgan Chase & Co. upped their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Evercore ISI reduced their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a report on Tuesday. Robert W. Baird reduced their target price on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. The Goldman Sachs Group increased their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $606.47.

Thermo Fisher Scientific Trading Up 0.3 %

Shares of TMO stock traded up $1.68 during trading hours on Wednesday, hitting $535.61. 907,641 shares of the company’s stock traded hands, compared to its average volume of 1,544,141. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The stock has a market cap of $204.45 billion, a PE ratio of 34.52, a price-to-earnings-growth ratio of 2.58 and a beta of 0.77. The stock’s 50 day simple moving average is $573.89 and its 200 day simple moving average is $563.61.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. Thermo Fisher Scientific’s payout ratio is 10.01%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,873,516.56. The disclosure for this sale can be found here. Insiders sold 22,000 shares of company stock worth $12,532,780 over the last three months. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.